$Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma$

Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma

Abstract Background The current standard of care for classical Hodgkin lymphoma (HL) is multiagent chemotherapy with or without radiation. In patients who relapse or fail to respond, additional high-dose chemotherapy with autologous hematopoietic stem cell transplantation (AHSCT) can improve progres...

Full description

Bibliographic Details
Main Authors:	Patrick B. Johnston, Lauren C. Pinter-Brown, Ghulam Warsi, Kristen White, Radhakrishnan Ramchandren
Format:	Article
Language:	English
Published:	BMC 2018-05-01
Series:	Experimental Hematology & Oncology
Subjects:	Clinical trial Everolimus Hodgkin lymphoma mTOR inhibitors Relapsed/refractory
Online Access:	http://link.springer.com/article/10.1186/s40164-018-0103-z

Similar Items

Everolimus as a single agent in refractory or relapsed Hodgkin's lymphoma: the Brazilian Named Patient Program Experience
by: Talita Máira Bueno da Silveira da Rocha, et al.

Novel Agents For Relapsed and Refractory Classical Hodgkin Lymphoma: A Review
by: Yujie Zhang, et al.
Published: (2022-07-01)

Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy
by: Michael P. Randall, et al.
Published: (2023-09-01)

Modern approaches in relapsed and refractory Hodgkin lymphoma treatment: literature review and own experience
by: Natalia S. Tsaplina, et al.
Published: (2022-11-01)

The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
by: Jeremy A. Meier, et al.
Published: (2022-02-01)

TREATMENT OF RELAPSE AND REFRACTORY HODGKIN LYMPHOMA
by: E. A. Baryakh
Published: (2017-06-01)

Immunosuppressive Microenvironment and Efficacy of PD-1 Inhibitors in Relapsed/Refractory Classic Hodgkin Lymphoma: Checkpoint Molecules Landscape and Macrophage Populations
by: Artem Gusak, et al.
Published: (2021-11-01)

Immunotoxin – a new treatment option in patients with relapsed and refractory Hodgkin lymphoma
by: Novakovic Barbara Jezersek
Published: (2015-12-01)

Assessment of Effectiveness and Adverse Effect of New Combination Chemotherapy (irinotecan, cisplatin, and dexamethasone) in Relapse and Refractory Hodgkin Lymphoma
by: Mahdi Tabarraee, et al.
Published: (2023-07-01)

Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities
by: Julio Pascual, et al.
Published: (2017-05-01)

TARGETED THERAPY WITH BRENTUXIMAB VEDOTIN IN RELAPSED AND REFRACTORY FORMS OF CLASSICAL HODGKIN LYMPHOMA
by: E. A. Demina
Published: (2017-11-01)

Targeted therapy and hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma in pediatric and adolescent patients: a pilot protocol results
by: Natalia S. Tsaplina, et al.
Published: (2023-05-01)

GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study
by: Mani Ramzi, et al.
Published: (2015-03-01)

Recomendaciones para el uso de everolimus en trasplante renal de novo: falsas creencias, mitos y realidades
by: Julio Pascual, et al.
Published: (2017-05-01)

Two cases of eczematous eruptions caused by everolimus
by: Minako Habu, et al.
Published: (2019-10-01)

Salvage radiotherapy for relapsed/refractory non‐Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy
by: Nikhil Yegya-Raman, et al.
Published: (2023-03-01)

Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents
by: Muhammad Salman Faisal, et al.
Published: (2023-04-01)

Novel Salvage Therapy Options for Initial Treatment of Relapsed/Refractory Classical Hodgkin’s Lymphoma: So Many Options, How to Choose?
by: Radhika Takiar, et al.
Published: (2022-07-01)

Antimycobacterial Effects of Everolimus in a Human Granuloma Model
by: David Ashley, et al.
Published: (2020-06-01)

Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies
by: Karantanos T, et al.
Published: (2017-05-01)

IGF-1 influences Everolimus activity in medullary thyroid carcinoma
by: Erica eGentilin, et al.
Published: (2015-05-01)

Stem-Cell Transplantation in Adult Patients with Relapsed/Refractory Hodgkin Lymphoma
by: Sonja Genadieva Stavrik, et al.
Published: (2021-10-01)

Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma
by: Valiollah Mehrzad, et al.
Published: (2017-01-01)

Genome-wide association study for biomarker identification of Rapamycin and Everolimus using a lymphoblastoid cell line system
by: Jing eJiang, et al.
Published: (2013-08-01)

Single or tandem autologous stem cell transplantation for treating Chinese patients with refractory/relapsed classical Hodgkin lymphoma
by: Chen Zhang, et al.
Published: (2023-05-01)

CLINICAL CHARACTERISTICS AND TREATMENT RESULTS OF PEDIATRIC RELAPSED/REFRACTORY NON-HODGKIN’S LYMPHOMAS
by: T. T. Valiev
Published: (2018-07-01)

Sirolimus as Rescue Therapy for Refractory/Relapsed Immune Thrombocytopenia: Results of a Single-Center, Prospective, Single-Arm Study
by: Yimei Feng, et al.
Published: (2020-03-01)

Upregulation of Peroxiredoxin-2 in Well-Differentiated Pancreatic Neuroendocrine Tumors and Its Utility as a Biomarker for Predicting the Response to Everolimus
by: Eui Joo Kim, et al.
Published: (2020-11-01)

Defining the Magnetic Resonance Features of Renal Lesions and Their Response to Everolimus in a Transgenic Mouse Model of Tuberous Sclerosis Complex
by: Shubhangi Agarwal, et al.
Published: (2022-06-01)

Efficacy and safety of Everolimus in children with TSC - associated epilepsy – Pilot data from an open single-center prospective study
by: Sharon Samueli, et al.
Published: (2016-11-01)

Outcome of Pregnancy and Labour in a Patient with Hodgkin’s Lymphoma (Clinical Case)
by: A. A. Borscheva, et al.
Published: (2019-09-01)

Chronic Sulforaphane Administration Inhibits Resistance to the mTOR-Inhibitor Everolimus in Bladder Cancer Cells
by: Saira Justin, et al.
Published: (2020-06-01)

Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies
by: Theodoros P. Vassilakopoulos, et al.
Published: (2019-07-01)

mTOR Pathway Expression as Potential Predictive Biomarker in Patients with Advanced Neuroendocrine Tumors Treated with Everolimus
by: Fabio Gelsomino, et al.
Published: (2020-05-01)

Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma
by: Shinichi Makita, et al.
Published: (2022-12-01)

Real World Evidence of CAR T-Cell Therapies for the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: A Monocentric Experience
by: Beatrice Casadei, et al.
Published: (2021-09-01)

Combination of everolimus and low-dose tacrolimus controls histological liver allograft injury as sufficiently as high-dose tacrolimus
by: Emily A. Bosselmann, et al.
Published: (2023-04-01)

Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations
by: Birgit Burkhardt, et al.
Published: (2021-04-01)

The role of radiotherapy in patients with refractory Hodgkin's lymphoma after treatment with brentuximab vedotin and/or immune checkpoint inhibitors
by: Ruizhi Zhao, et al.
Published: (2024-03-01)

Co-treatment With Everolimus, an mTOR-Specific Antagonist, or Downregulation of ELK1 Enhances the Sensitivity of Pancreatic Cancer Cells to Genistein
by: Tianyu Li, et al.
Published: (2021-09-01)